alimera-sciences-inc-logo.jpg
Alimera Sciences Reports Fourth Quarter and FY 2021 Results
February 24, 2022 08:00 ET | Alimera Sciences, Inc.
Fourth Quarter Highlights: Consolidated Net Revenue of $14 Million Up 15% vs. Third Quarter of 2021; Up 1% vs. Fourth Quarter of 2020 Full Year 2021 Highlights: Consolidated Net Revenue of $59...
alimera-sciences-inc-logo.jpg
Phase 4 PALADIN Study with ILUVIEN® Published in Peer-Reviewed Journal Ophthalmology
February 23, 2022 08:00 ET | Alimera Sciences, Inc.
Best corrected visual acuity and central subfield thickness were significantly improved at 36 monthsILUVIEN treatment resulted in a 70.5% reduction in treatment burdenResults confirm that use of prior...
alimera-sciences-inc-logo.jpg
Alimera Sciences to Report Fourth Quarter and Full Year 2021 Financial Results on Thursday, February 24, 2022, and Provide Corporate Update
February 17, 2022 08:00 ET | Alimera Sciences, Inc.
ATLANTA, Feb. 17, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to...
alimera-sciences-inc-logo.jpg
Alimera Sciences Announces Launch of ILUVIEN® for Uveitis in Spain
February 07, 2022 08:00 ET | Alimera Sciences, Inc.
ATLANTA, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners...
alimera-sciences-inc-logo.jpg
Alimera Sciences to Present at the MicroCap Rodeo Winter Wonderland Best Ideas Virtual Investor Conference
February 04, 2022 08:00 ET | Alimera Sciences, Inc.
ATLANTA, Feb. 04, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners...
alimera-sciences-inc-logo.jpg
Alimera Sciences to Participate in Upcoming January 2022 Investor Conferences
January 05, 2022 08:00 ET | Alimera Sciences, Inc.
ATLANTA, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to...
alimera-sciences-inc-logo.jpg
Alimera Sciences Welcomes Ophthalmic Strategic Consultant Erin Parsons to Its Board of Directors
December 01, 2021 07:30 ET | Alimera Sciences, Inc.
ATLANTA, Dec. 01, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners...
alimera-sciences-inc-logo.jpg
Alimera Sciences to Participate in Upcoming November 2021 Investor Conferences
November 09, 2021 13:16 ET | Alimera Sciences, Inc.
ATLANTA, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners...
alimera-sciences-inc-logo.jpg
Alimera Sciences Announces Third Quarter 2021 Financial Results
October 28, 2021 07:30 ET | Alimera Sciences, Inc.
Consolidated Net Revenue of $12.2 Million Down 2% vs. Third Quarter of 2020 and Up 14% vs. Second Quarter of 2021U.S. End User Demand up 15% vs. Third Quarter of 2020 and Second Quarter of 2021 ...
alimera-sciences-inc-logo.jpg
Alimera Sciences to Report Third Quarter 2021 Financial Results on Thursday, October 28, 2021, and Provide Corporate Update
October 21, 2021 08:00 ET | Alimera Sciences, Inc.
ATLANTA, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera) a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners...